A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas

[1]  B. Goh,et al.  A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells , 2008, Investigational New Drugs.

[2]  M. Sznol,et al.  Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. , 2007, Leukemia research.

[3]  G. Pond,et al.  A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium , 2007, Investigational New Drugs.

[4]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  E. Eisenhauer,et al.  Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161) , 2007, Investigational New Drugs.

[6]  H. Burris,et al.  A phase II study of triapine in combination with gemcitabine (G) in patients (pts) with unresectable or metastatic pancreatic cancer (PC). , 2006, Journal of Clinical Oncology.

[7]  David L Rimm,et al.  Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. , 2006, Cancer research.

[8]  K. Camphausen,et al.  In vitro and In vivo Radiosensitization Induced by the Ribonucleotide Reductase Inhibitor Triapine (3-Aminopyridine-2-Carboxaldehyde-Thiosemicarbazone) , 2006, Clinical Cancer Research.

[9]  E. Eisenhauer,et al.  Recognition and management of methemoglobinemia and hemolysis in a G6PD‐deficient patient on experimental anticancer drug Triapine , 2006, American journal of hematology.

[10]  D. V. Von Hoff,et al.  A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  R. Labianca,et al.  Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  W. Miller,et al.  Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Sznol,et al.  Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  David L Rimm,et al.  Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. , 2004, The American journal of pathology.

[15]  Thierry Buclin,et al.  Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance , 2004, Clinical pharmacology and therapeutics.

[16]  M. Sznol,et al.  Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  M. Fromm.  The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. , 2002, Advanced drug delivery reviews.

[18]  D. Rimm,et al.  Automated subcellular localization and quantification of protein expression in tissue microarrays , 2002, Nature Medicine.

[19]  N. Savaraj,et al.  Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule , 2002, Cancer Chemotherapy and Pharmacology.

[20]  Daniel G Haller,et al.  Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G. Colucci,et al.  Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma , 2002, Cancer.

[22]  R. Kim,et al.  Identification of functionally variant MDR1 alleles among European Americans and African Americans , 2001, Clinical pharmacology and therapeutics.

[23]  D. Sargent,et al.  A three-outcome design for phase II clinical trials. , 2001, Controlled clinical trials.

[24]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[26]  A. Sartorelli,et al.  Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. , 1999, Advances in enzyme regulation.

[27]  A. Sartorelli,et al.  Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase. , 1997, Biochemical pharmacology.

[28]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. V. Von Hoff,et al.  A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Y. Yen,et al.  Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells. , 1995, Cancer research.

[31]  A. Sartorelli,et al.  Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. , 1994, Biochemical pharmacology.

[32]  Y. Yen,et al.  Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine. , 1994, Cancer research.

[33]  C. Sol,et al.  Rapid purification of hepatitis B virus DNA from serum , 1991, Journal of clinical microbiology.

[34]  J. Wright,et al.  Relationships between sensitivity to hydroxyurea and 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone (MAIO) and ribonucleotide reductase RNR2 mRNA levels in strains of Saccharomyces cerevisiae. , 1989, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[35]  J. G. Cory,et al.  Alterations in the components of ribonucleotide reductase in hydroxyurea-resistant hamster cells , 1983, Bioscience reports.

[36]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[37]  M. Sznol,et al.  A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. , 2008, Leukemia research.

[38]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[39]  L. Vahdat,et al.  A phase II trial of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP) in patients with metastatic breast cancer. , 2004, Journal of Clinical Oncology.

[40]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[41]  I. Bassukas,et al.  An in vivo study on the synchronizing effect of hydroxyurea. , 1988, Experimental cell research.

[42]  D.,et al.  Regression Models and Life-Tables , 2022 .